News | April 27, 2023
Biocon approves NCD issue
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Bridging the gap between histopathology and molecular pathology
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
The business and product range of Ipca and that of Unichem complements each others business and product range
A special technique of jet injection is used to make vaccination almost painless and totally needleless.
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Metronidazole is an antibiotic used on the skin to treat a certain skin disorder known as rosacea
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Apollo continues to invest in genomics technology and research for better patient care
Subscribe To Our Newsletter & Stay Updated
